Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone.

Levy MJ, Gleeson FC, Topazian MD, Fujii-Lau LL, Enders FT, Larson JJ, Mara K, Abu Dayyeh BK, Alberts SR, Hallemeier CL, Iyer PG, Kendrick ML, Mauck WD, Pearson RK, Petersen BT, Rajan E, Takahashi N, Vege SS, Wang KK, Chari ST.

Clin Gastroenterol Hepatol. 2018 Sep 11. pii: S1542-3565(18)30878-4. doi: 10.1016/j.cgh.2018.08.040. [Epub ahead of print]

PMID:
30217513
2.

Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas.

Huffman BM, Westin G, Alsidawi S, Alberts SR, Nagorney DM, Halfdanarson TR, Mahipal A.

Pancreas. 2018 Sep;47(8):1003-1007. doi: 10.1097/MPA.0000000000001112.

PMID:
30036214
3.

Gastric cancer in Alaska Native people: A cancer health disparity.

Martinson HA, Shelby NJ, Alberts SR, Olnes MJ.

World J Gastroenterol. 2018 Jul 7;24(25):2722-2732. doi: 10.3748/wjg.v24.i25.2722.

4.

Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance).

Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):696-703. doi: 10.1158/1055-9965.EPI-17-0769. Epub 2018 Mar 21.

PMID:
29563133
5.

Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.

Jin Z, Hartgers ML, Sanhueza CT, Shubert CR, Alberts SR, Truty MJ, Muppa P, Nagorney DM, Smyrk TC, Hassan M, Mahipal A.

Eur J Surg Oncol. 2018 May;44(5):677-683. doi: 10.1016/j.ejso.2018.02.008. Epub 2018 Feb 16.

PMID:
29506768
6.

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.

Kim RD, Alberts SR, Peña C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A, Grilley-Olson JE.

Br J Cancer. 2018 Feb 20;118(4):462-470. doi: 10.1038/bjc.2017.428. Epub 2018 Jan 18.

7.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.

Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.

JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899.

PMID:
28983557
8.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ.

J Clin Oncol. 2017 Nov 10;35(32):3671-3677. doi: 10.1200/JCO.2017.74.2130. Epub 2017 Oct 4.

PMID:
28976791
9.

Mutation in BRAF V600E-Reply.

Sinicrope FA, Shi Q, Alberts SR.

JAMA Oncol. 2017 Sep 1;3(9):1285-1286. doi: 10.1001/jamaoncol.2017.1474. No abstract available.

PMID:
28617912
10.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S.

J Natl Compr Canc Netw. 2017 May;15(5):563-573.

11.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J.

Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052.

12.

Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance).

Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR.

J Gastrointest Oncol. 2017 Feb;8(1):1-11. doi: 10.21037/jgo.2016.12.13.

13.

MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.

Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, Sinicrope FA, Goel A.

Sci Rep. 2017 Mar 6;7:43393. doi: 10.1038/srep43393.

14.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw272. Print 2017 May.

15.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.

Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.

JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.

16.

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).

Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR.

Target Oncol. 2017 Apr;12(2):201-209. doi: 10.1007/s11523-016-0467-0.

17.

EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.

Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST.

Gastrointest Endosc. 2017 Jul;86(1):161-169. doi: 10.1016/j.gie.2016.11.014. Epub 2016 Nov 23.

18.

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).

Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR.

Oncologist. 2016 Dec;21(12):1509-1521. Epub 2016 Nov 23.

19.

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA.

Ann Oncol. 2016 Dec;27(12):2196-2203. doi: 10.1093/annonc/mdw423. Epub 2016 Oct 20.

PMID:
27765757
20.

Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer.

Renfro LA, Zhang N, Lopatin M, Chao C, Alberts SR.

Clin Colorectal Cancer. 2017 Mar;16(1):23-30. doi: 10.1016/j.clcc.2016.07.016. Epub 2016 Aug 9.

21.

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

J Geriatr Oncol. 2016 Nov;7(6):422-429. doi: 10.1016/j.jgo.2016.07.002. Epub 2016 Jul 25.

22.

Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR.

Cancer Lett. 2016 Sep 28;380(1):163-73. doi: 10.1016/j.canlet.2016.05.017. Epub 2016 May 20.

23.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.

Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR; Alliance for Clinical Trials in Oncology.

Int J Cancer. 2016 Sep 1;139(5):986-95. doi: 10.1002/ijc.30135. Epub 2016 May 9.

24.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8.

25.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Mar 10;34(8):843-53. doi: 10.1200/JCO.2015.63.0558. Epub 2016 Jan 25.

26.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB.

Pharmacogenet Genomics. 2016 Mar;26(3):133-7. doi: 10.1097/FPC.0000000000000197.

27.

Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People.

Redwood DG, Asay ED, Blake ID, Sacco PE, Christensen CM, Sacco FD, Tiesinga JJ, Devens ME, Alberts SR, Mahoney DW, Yab TC, Foote PH, Smyrk TC, Provost EM, Ahlquist DA.

Mayo Clin Proc. 2016 Jan;91(1):61-70. doi: 10.1016/j.mayocp.2015.10.008. Epub 2015 Oct 28.

28.

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).

Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR; Alliance for Clinical Trials in Oncology.

Clin Cancer Res. 2015 Dec 1;21(23):5294-304. doi: 10.1158/1078-0432.CCR-15-0527. Epub 2015 Jul 17.

29.

Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.

Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2015 Jul 9;107(10). pii: djv186. doi: 10.1093/jnci/djv186. Print 2015 Oct.

30.

MiR-320e is a novel prognostic biomarker in colorectal cancer.

Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A.

Br J Cancer. 2015 Jun 30;113(1):83-90. doi: 10.1038/bjc.2015.168. Epub 2015 Jun 2.

31.

Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers.

Cheville AL, Alberts SR, Rummans TA, Basford JR, Lapid MI, Sloan JA, Satele DV, Clark MM.

J Pain Symptom Manage. 2015 Sep;50(3):321-7. doi: 10.1016/j.jpainsymman.2015.03.005. Epub 2015 May 12.

32.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD.

J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.

33.

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group; Adjuvant Colon Cancer Endpoints ACCENT Group.

Ann Oncol. 2015 May;26(5):950-8. doi: 10.1093/annonc/mdv073. Epub 2015 Feb 19.

34.

Low level of hepatitis B virus screening among patients receiving chemotherapy.

Wi CI, Loo NM, Larson JJ, Moynihan TJ, Madde NR, Grendahl DC, Alberts SR, Kim WR.

Clin Gastroenterol Hepatol. 2015 May;13(5):970-5; quiz e51. doi: 10.1016/j.cgh.2014.10.032. Epub 2014 Nov 6.

35.

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB.

J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju298. doi: 10.1093/jnci/dju298. Print 2014 Dec.

36.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju333. doi: 10.1093/jnci/dju333. Print 2014 Dec.

37.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.

Gastroenterology. 2015 Jan;148(1):88-99. doi: 10.1053/j.gastro.2014.09.041. Epub 2014 Oct 8.

38.

Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer.

Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J.

Pharmacoeconomics. 2014 Dec;32(12):1231-43. doi: 10.1007/s40273-014-0207-1.

39.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2014 Jun 12;106(7). pii: dju106. doi: 10.1093/jnci/dju106. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2014 Jul;106(7). doi:10.1093/jnci/dju228.

40.

Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.

Sio TT, Martenson JA Jr, Haddock MG, Novotny PJ, Gores GJ, Alberts SR, Miller RC, Heimbach JK, Rosen CB.

Am J Clin Oncol. 2016 Jun;39(3):271-5. doi: 10.1097/COC.0000000000000056.

41.

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.

Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J.

Clin Cancer Res. 2014 Aug 15;20(16):4176-85. doi: 10.1158/1078-0432.CCR-13-2024. Epub 2014 Jun 9.

42.

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.

Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR.

Invest New Drugs. 2014 Aug;32(4):710-6. doi: 10.1007/s10637-014-0096-3. Epub 2014 Apr 18.

PMID:
24740268
43.

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).

Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB.

Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11.

44.

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR.

Oncologist. 2014 May;19(5):492-7. doi: 10.1634/theoncologist.2013-0401. Epub 2014 Apr 7.

45.

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology.

Clin Cancer Res. 2014 Jun 1;20(11):3033-43. doi: 10.1158/1078-0432.CCR-13-3140. Epub 2014 Mar 31.

46.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.

Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR; Alliance for Clinical Trials in Oncology.

Clin Colorectal Cancer. 2014 Jun;13(2):100-9. doi: 10.1016/j.clcc.2013.12.002. Epub 2013 Dec 28.

47.

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.

J Clin Oncol. 2013 Oct 10;31(29):3664-72. doi: 10.1200/JCO.2013.48.9591. Epub 2013 Sep 9.

48.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group.

Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27.

49.

Alternate dosing of cetuximab for patients with metastatic colorectal cancer.

Hubbard JM, Alberts SR.

Gastrointest Cancer Res. 2013 Mar;6(2):47-55.

50.

Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.

Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q.

Cancer. 2013 Aug 1;119(15):2765-70. doi: 10.1002/cncr.28133. Epub 2013 May 8.

Supplemental Content

Loading ...
Support Center